Keren Haruvi reelected chair of AAM’s board of directors
The board of directors of the Association for Accessible Medicines has reelected Keren Haruvi, president of Sandoz North America, as chair for a second one-year term. The board also reconfirmed for a second term Bob Hoffman, chief commercial officer of U.S. generics for Lupin Pharmaceuticals, as vice chair of the board and Jeff Burd, president and CEO, North America of Ajanta Pharma USA as treasurer.
“It has been an honor to lead our AAM board and I’m excited to continue as chair,” said Haruvi. “Together, we will work to foster predicable and sustainable access to high quality generic and biosimilar medicines for America’s patients; and focus on educating and working with our regulators, legislators, and the administration on the real threats facing our industry. I look forward to working with fellow board members and the AAM team to shine a light on the life-changing, positive impact of generic and biosimilar medicines.”
[Read more: AAM report: Generics, biosimilars generate $445B in savings]
Prior to her current role at Sandoz, Haruvi served as global head of M&A for Novartis after 14 years at Teva Pharmaceuticals.
John Murphy III, president and CEO of AAM, said, “Keren’s leadership has been invaluable, and we are thankful she will serve a second term in this role. With a stable and consistent Executive Committee, AAM will continue to protect the sustainability of our industry and help ensure lower-cost, vital generic and biosimilar medicines are always available to patients and hospitals.”
[Read more: Challenges continue, but generics companies see a bright future with biosimilars]